Study guide
6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
Key Takeaways Explain This Topic AI
Hypertensive emergency is defined by severe blood pressure elevation (typically SBP >180 mmHg or DBP >120 mmHg) accompanied by acute, life-threatening target organ damage, requiring ICU admission and intravenous pharmacotherapy.
Severe hypertension without acute target organ damage (called hypertensive urgency before the 2025 AHA/ACC guideline renamed it) is managed with oral therapy and follow-up over 24 to 48 hours; rapid IV lowering is unnecessary and potentially harmful.
The general target for hypertensive emergencies is to reduce mean arterial pressure (MAP) by no more than 20% to 25% within the first hour to prevent cerebral, myocardial, and renal watershed infarction.
Acute aortic dissection is the main exception: the 2022 ACC/AHA aortic disease guideline targets SBP below 120 mmHg (or the lowest pressure that maintains perfusion) and heart rate 60–80 bpm, starting IV beta-blockers before vasodilators.
First-line parenteral antihypertensives include titratable agents such as nicardipine, clevidipine, and labetalol; IV hydralazine should be avoided in most emergencies due to its delayed onset, prolonged duration, and unpredictable hypotensive response.
Last updated: October 2026
6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination specifications.
Diagnostic Definitions & Clinical Triage
A hypertensive crisis is defined by a severe, acute elevation in blood pressure, typically characterized by a systolic blood pressure (SBP) >180 mmHg and/or a diastolic blood pressure (DBP) >120 mmHg . The clinical management hinges entirely on the presence or absence of acute, evolving, life-threatening target organ damage (TOD) : HYPERTENSIVE CRISIS TRIAGE
- BP >180/120 mmHg
- │
Acute Target Organ Damage Present?
- │
- ┌──────────────────┴──────────────────┐
- ▼ ▼
- YES NO
- HYPERTENSIVE EMERGENCY HYPERTENSIVE URGENCY
- ┌──────────────────────────────────────┐ ┌──────────────────────────────────┐
- │ • Life-threatening organ dysfunction │ │ • No acute target organ damage │
- │ • ICU admission mandatory │ │ • Outpatient oral therapy │
- │ • Continuous IV antihypertensives │ │ • Avoid IV agents / rapid drops │
- │ • Goal: Reduce MAP ≤20–25% in 1 hour │ │ • Goal: Normalize over 24–48 hrs │
- └──────────────────────────────────────┘ └──────────────────────────────────┘
- Target Organ Damage Phenotypes in Hypertensive Emergencies
Neurologic : Hypertensive encephalopathy (altered mental status, severe headache, seizures, papilledema), acute intracranial hemorrhage (intracerebral hemorrhage, subarachnoid hemorrhage), acute ischemic stroke.
Cardiovascular : Acute aortic dissection (Stanford Type A or B), acute coronary syndromes (STEMI, NSTEMI), acute cardiogenic pulmonary edema (SCAPE).
Renal : Acute kidney injury / acute renal failure, rapidly progressive glomerulonephritis, or thrombotic microangiopathy (microangiopathic hemolytic anemia with fragmented red cells / schistocytes).
Obstetric : Preeclampsia with severe features, eclampsia, HELLP syndrome.
Hyperadrenergic States : Pheochromocytoma crisis, illicit sympathomimetic toxicity (cocaine, methamphetamine), severe clonidine withdrawal, monoamine oxidase inhibitor (MAOI)-tyramine dietary interactions.
Hypertensive Urgency: The Danger of Overtreatment
Hypertensive urgency is defined by severe blood pressure elevation (SBP >180 mmHg or DBP >120 mmHg) in an otherwise stable patient without evidence of acute target organ damage . The 2025 AHA/ACC high blood pressure guideline replaces the term with severe hypertension (without acute target organ damage), but exam items may use either name. Patients may complain of mild non-specific symptoms such as tension-type headache, epistaxis, or anxiety, but their diagnostic evaluation (neurologic exam, ECG, troponin, basic metabolic panel, urinalysis) shows no acute dysfunction.
Warning
The Cardinal Pitfall of Hypertensive Urgency : Hypertensive urgency does NOT require emergency department admission, intravenous antihypertensives, or acute rapid lowering of blood pressure. Chronic hypertension shifts the vascular autoregulatory curve to the right. Rapid reduction of blood pressure with parenteral agents or sublingual immediate-release nifedipine drops perfusion pressure below this shifted autoregulatory threshold, inducing cerebral watershed infarction, acute myocardial infarction, and acute tubular necrosis. Hypertensive urgency is managed in the outpatient setting with oral antihypertensives titrated over 24 to 48 hours.
- Blood Pressure Reduction Targets & Cerebral Autoregulation CEREBRAL AUTOREGULATION CURVE
- Cerebral
- Blood Flow
- ▲
- │ Normal Range (MAP 60–120 mmHg)
- │ ┌─────────────────────────┐
- │ / \ Chronic Hypertensive Shift
- │ / \ ┌───────────────────────┐
- │ / \/ \
- │ / \ \
- │ / \ \
- └───────┴─────────────────────────────────────┴──────────────────────────┴──►
- 50 100 150 200
- Mean Arterial Pressure (MAP, mmHg)
In healthy adults, cerebral blood flow is held constant across a mean arterial pressure (MAP) range of approximately 60 to 120 mmHg. In patients with chronic hypertension, functional vascular remodeling shifts this autoregulation curve rightward (e.g., MAP range 110 to 160 mmHg) to shield capillary beds from elevated systemic pressures. Lowering MAP too rapidly places the patient in the hypoperfusion zone on the left of their shifted curve.
The Standard Hypertensive Emergency Target Schedule
For the vast majority of hypertensive emergencies, the blood pressure reduction schedule follows three distinct phases:
First Hour : Reduce Mean Arterial Pressure (MAP = DBP + 1/3[SBP − DBP]) by no more than 20% to 25% (or reduce SBP/DBP by ~15%).
Hours 2 to 6 : If the patient remains neurologically and clinically stable, lower blood pressure gradually toward 160/100 to 110 mmHg .
Hours 24 to 48 : Gradually normalize blood pressure toward outpatient baseline targets using oral maintenance regimens.
Critical Clinical Exceptions to the Standard Schedule
Acute Aortic Dissection :
Hemodynamic Goal : The 2022 ACC/AHA aortic disease guideline recommends treating to an SBP below 120 mmHg (or the lowest pressure that maintains end-organ perfusion) and a heart rate of 60 to 80 bpm , achieved promptly with arterial-line monitoring in an ICU. Older teaching and the ESC set a heart rate goal below 60 bpm.
Physiologic Rationale : The propagation of an aortic dissection flap is governed by aortic wall shear stress (the rate of change of left ventricular pressure over time, dP/dt ) and transmural distending pressure (SBP).
Mandatory Administration Sequence : An intravenous beta-blocker must be administered FIRST (e.g., esmolol continuous infusion or IV labetalol boluses) to reduce heart rate and cardiac contractility (blunting dP/dt) BEFORE or simultaneously with initiating an intravenous vasodilator (e.g., nicardipine or nitroprusside). If beta-blockers are contraindicated, an IV non-dihydropyridine calcium channel blocker (diltiazem) is reasonable for rate control. Administering a vasodilator alone stimulates baroreceptor-mediated reflex sympathetic tachycardia, increasing dP/dt and accelerating dissection propagation or aortic rupture.
Acute Ischemic Stroke (AIS) :
Candidates for Thrombolytic Therapy (Alteplase / Tenecteplase) : Blood pressure must be lowered to <185/110 mmHg prior to fibrinolysis and maintained <180/105 mmHg for at least 24 hours post-thrombolysis to prevent fatal hemorrhagic transformation.
Non-Reperfusion Candidates : Allow "permissive hypertension" to maintain collateral perfusion to the ischemic penumbra. Do NOT treat blood pressure unless SBP >220 mmHg or DBP >120 mmHg ; if treatment is indicated, reduce MAP by only 15% over the first 24 hours.
Severe Preeclampsia / Eclampsia :
Rapidly lower SBP to <160 mmHg and DBP to <110 mmHg to prevent maternal intracerebral hemorrhage and placental abruption while preserving uteroplacental blood flow. First-line parenteral agents include IV labetalol, IV hydralazine, or oral extended-release nifedipine, paired with IV magnesium sulfate for eclampsia prophylaxis.
Parenteral Antihypertensive Formulary Comparison
Agent Class & Mechanism Onset & Duration Initial Dosing & Titration Major Adverse Effects & Precautions
Nicardipine Dihydropyridine CCB (Arterial selective) Onset: 5–15 min; Duration: 30–60 min 5 mg/h IV; titrate by 2.5 mg/h q5–15min (max 15 mg/h). Down-titrate to 3 mg/h at goal. Phlebitis (rotate peripheral line q12h; central line preferred), headache, reflex tachycardia. Avoid in advanced aortic stenosis.
Clevidipine 3rd-Gen Dihydropyridine CCB (Esterase cleared) Onset: 2–4 min; Duration: 5–15 min 1–2 mg/h IV; double q90s initially until near goal, then titrate q5–10min (max 32 mg/h). Lipid emulsion (2 kcal/mL); strict egg/soy allergy contraindication; strict 12-hour vial hang time limit; hypertriglyceridemia.
Labetalol Combined α1- and non-selective β-blocker (1:7 IV) Onset: 2–5 min; Duration: 2–4 hours 10–20 mg IV push over 2 min; repeat q10min with doubling doses (20, 40, 80 mg; max 300 mg) or 1–8 mg/min infusion. Bradycardia, heart block, bronchospasm. Contraindicated in acute decompensated HFrEF and severe asthma. Excellent in dissection and stroke.
Esmolol Ultra-short cardioselective β1-blocker Onset: 1–2 min; Duration: 10–20 min 500 mcg/kg IV bolus over 1 min, then 50 mcg/kg/min infusion; titrate by 50 mcg/kg/min q5–10min (max 300 mcg/kg/min). Bradycardia, hypotension, bronchospasm at high doses. Ideal agent for heart rate and dP/dt control in acute aortic dissection.
Hydralazine Direct arteriolar vasodilator Onset: 10–30 min; Duration: 2–4 hours (up to 8h) 10–20 mg IV push q4–6h (max 20 mg/dose). Delayed onset, unpredictable duration, "dose stacking" causing profound hypotension, reflex tachycardia. Avoid in ACS/dissection; reserve for pregnancy.
- Clinical Nuances of Key Parenteral Agents
- 1. Nicardipine
Nicardipine provides predictable, titratable arterial vasodilation without depressing cardiac conduction or contractility. It preserves cerebral, coronary, and renal perfusion, making it the premier first-line agent for acute ischemic stroke, intracerebral hemorrhage, and hypertensive encephalopathy. Because the concentrated infusion causes local vascular irritation, peripheral intravenous infusion sites must be changed every 12 hours to prevent thrombophlebitis.
2. Clevidipine
Clevidipine is an ultra-short-acting dihydropyridine calcium channel blocker metabolized rapidly by blood and tissue esterases (plasma half-life ~1 minute). Its clearance is independent of renal or hepatic impairment. However, clinicians must manage three unique pharmaceutical properties:
Lipid Formulation : Formulated in a 20% lipid emulsion delivering 2.0 kcal/mL . These calories must be incorporated into total nutritional intake in critically ill patients.
Allergy Contraindications : Strictly contraindicated in patients with severe allergies to soybeans, soy products, eggs, or egg products .
Microbial Safety & Hang Time : The lipid emulsion vehicle supports rapid microbial proliferation. The manufacturer specifies a strict maximum hang time of 12 hours per vial and infusion line ; any remaining drug must be discarded.
3. Labetalol
Labetalol blocks alpha-1, beta-1, and beta-2 adrenergic receptors. When administered intravenously, the ratio of alpha-to-beta blockade is 1:7 (in contrast to 1:3 for oral formulations). This predominant beta-blocking effect lowers systemic vascular resistance without triggering reflex tachycardia, making labetalol particularly valuable in acute aortic dissection, pregnancy-induced hypertensive emergencies, and acute stroke. It must be avoided in acute decompensated heart failure with reduced ejection fraction, sinus bradycardia, high-degree heart block, or severe bronchospastic asthma.
4. The Pitfalls of IV Hydralazine
Intravenous hydralazine is frequently overutilized in emergency settings despite serious pharmacological disadvantages:
Delayed Onset & Unpredictable Nadir : The peak hypotensive effect does not manifest for 10 to 30 minutes following an IV push.
Prolonged, Erratic Duration : Its hypotensive effect persists unpredictably for 2 to 4 hours (and up to 8 hours), preventing smooth titration.
Dose Stacking Danger : Inexperienced clinicians often administer repeated boluses at 10-minute intervals when blood pressure fails to drop immediately. This "stacking" leads to catastrophic late-onset hypotension, watershed cerebral ischemia, and myocardial infarction.
Sympathetic Reflex : Triggers pronounced baroreceptor-mediated reflex tachycardia, increasing myocardial oxygen demand and aortic shear stress.
Modern Role : Hydralazine should be avoided as a routine first-line agent in hypertensive emergencies, remaining acceptable primarily in severe preeclampsia/eclampsia where clinical experience is extensive.